Showing results (681-690 of 718) with videos related to
Sort By:
Pageof 72
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.Molecular Cancer Therapeutics|September 14, 2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung CancerJulia Judd, Nagla Abdel Karim, Hina Khan, et al.JCO Precision Oncology|February 8, 2024
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.British Journal of Cancer|September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David Hong, et al.Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.Journal for Immunotherapy of Cancer|June 4, 2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastomaErin F Simonds, Edbert D Lu, Oscar Badillo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell CarcinomaElizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.Pageof 72